Synaptic Dysfunction in Alzheimer's Disease
Overview
flowchart TD
A["Abeta Oligomers"] --> B["Synaptic Receptor Binding"]
A --> C["Presynaptic Vesicle Depletion"]
B --> D["NMDAR Dysfunction"]
B --> E["AMPAR Internalization"]
C --> F["Reduced Neurotransmitter Release"]
D --> G["Ca2+ Dysregulation"]
E --> H["Reduced Synaptic Strength"]
G --> I["LTP Impairment / LTD Enhancement"]
H --> I
F --> I
J["Tau Mislocalization to Dendrites"] --> E
J --> D
I --> K["Synapse Loss"]
K --> L["Cognitive Decline"]
Synaptic Signaling Pathways in AD
```mermaid
flowchart LR
subgraph Presynaptic
SV["Synaptic<br/>Vesicles"] --> Release["Glutamate<br/>Release"]
end
subgraph Postsynaptic_Density
AMPAR["AMPA<br/>Receptor"] --> AMPAR_P["Phosphorylation"]
NMDAR["NMDA<br/>Receptor"] --> Ca_Influx["Ca2+ Influx"]
PSD95["PSD-95"] --> Scaffolding["Scaffolding"]
CaMKII["CaMKII"] --> LTP["LTP Induction"]
Calc["Calcineurin"] --> LTD["LTD Induction"]
end
subgraph AD_Pathology
Abeta["Abeta Oligomers"] -.->|"Inhibit"| NMDAR
Abeta -->|"Enhance"| Calc
Abeta -->|"Reduce"| PSD95
Tau["Tau"] -.->|"Disrupt"| AMPAR
Tau -->|"Impair"| CaMKII
end
Release --> AMPAR
Release --> NMDAR
Ca_Influx --> CaMKII
Ca_Influx --> Calc
AMPAR_P --> Synapse_Strength["Synaptic<br/>Strength"]
LTP --> Synapse_Strength
LTD -.->|"Reduce"| Synapse_Strength
...Synaptic Dysfunction in Alzheimer's Disease
Overview
Mermaid diagram (expand to render)
Synaptic Signaling Pathways in AD
Mermaid diagram (expand to render)
Introduction
Alzheimer's disease (AD) is characterized by two hallmark proteinopathies: extracellular amyloid-β (Aβ) plaques composed of Aβ peptides derived from [amyloid precursor protein](/entities/app-protein) (APP) processing, and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated [tau protein](/proteins/tau). While these pathological hallmarks have been central to AD research for decades, the synaptic dysfunction hypothesis has emerged as a critical framework for understanding how these proteinopathies translate into cognitive decline ([Selkoe, 2002](https://pubmed.ncbi.nlm.nih.gov/11945065/)).
The synapse represents the fundamental unit of neural communication and is particularly vulnerable in AD. Research from the Seattle Alzheimer's Disease Brain Initiative (SEA-AD) and other consortia has revealed that synaptic dysfunction represents one of three major molecular subtypes in AD, alongside tau-mediated neurodegeneration and amyloid-β-driven neuroinflammation ([Nguyen et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38145097/)). This recognition has shifted therapeutic strategies toward protecting synaptic function as a primary goal.
Molecular Mechanisms of Synaptic Impairment
Amyloid-Beta Synaptic Effects
Aβ exerts bidirectional, concentration-dependent effects on synaptic function. At physiological concentrations (picomolar range), Aβ may facilitate synaptic transmission and plasticity, while pathological concentrations (nanomolar range) progressively impair synaptic function ([Puzzo et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18691953/)). This concentration-dependent relationship helps explain the preclinical versus clinical manifestations of AD pathology.
Presynaptic Mechanisms
Aβ oligomers disrupt presynaptic function through multiple mechanisms:
PtdIns(4,5)P2 Depletion: Aβ oligomers reduce phosphoinositol PtdIns(4,5)P2 (PIP2) levels in presynaptic terminals, affecting synaptotagmin-1 docking and fusion machinery ([Berman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18305482/))
Synaptic Vesicle Pool Depletion: Chronic Aβ exposure depletes the readily releasable pool of synaptic vesicles, reducing the capacity for sustained neurotransmitter release
Ca²⁺ Dysregulation: Aβ interacts with voltage-gated calcium channels and ryanodine receptors, causing pathological presynaptic calcium elevations that impair vesicle cycling
Mitochondrial Dysfunction: Aβ accumulates in presynaptic mitochondria, impairing ATP production needed for synaptic vesicle recycling and neurotransmitter releasePostsynaptic Mechanisms
Postsynaptic Aβ toxicity manifests through several interconnected pathways:
AMPA Receptor Internalization: Aβ promotes the internalization of AMPA receptors through calcineurin-dependent dephosphorylation, reducing synaptic strength ([Liu et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20106950/))
NMDA Receptor Dysfunction: Aβ alters NMDA receptor subunit composition, favoring extrasynaptic over synaptic NMDAR activation, which promotes LTD-like mechanisms ([Papadia et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15959452/))
PSD-95 Degradation: Aβ reduces postsynaptic density protein-95 (PSD-95) levels, disrupting the postsynaptic scaffolding that anchors receptors and signaling molecules
BDNF-TrkB Signaling Impairment: Aβ impairs brain-derived neurotrophic factor (BDNF) signaling through TrkB receptors, compromising synaptic plasticity maintenanceWhile traditionally viewed as an axonal protein, tau localizes to dendrites in AD brains where it exerts significant postsynaptic effects ([Hoover et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20445063/)):
Dendritic Tau Missorting: Hyperphosphorylated tau mislocalizes from axons to dendritic compartments, disrupting postsynaptic signaling
AMPA Receptor Trafficking Impairment: Tau interacts with the actin cytoskeleton and disrupts AMPA receptor trafficking to and from the synapse
NMDA Receptor Dysregulation: Dendritic tau modulates NMDA receptor function, contributing to calcium dysregulation
Synaptic Prion-like Propagation: Tau oligomers may propagate between synapses in a prion-like manner, spreading synaptic dysfunction ([Frost et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19136956/))
Fyn Kinase Activation: Tau recruits Fyn kinase to synapses, leading to NMDA receptor hyperphosphorylation and excitotoxicityAPOE4 and Synaptic Vulnerability
[Apolipoprotein E](/proteins/apoe) (APOE) ε4 allele represents the strongest genetic risk factor for late-onset AD ([Corder et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8357026/)). APOE4 exacerbates synaptic dysfunction through:
Cholesterol Transport Impairment: APOE4 is less effective than APOE3 at transporting cholesterol to [neurons](/entities/neurons), affecting synaptic membrane composition and function
Reduced Spine Density: APOE4-expressing neurons show reduced dendritic spine density in culture and in vivo
Enhanced Calcineurin Activation: APOE4 promotes calcineurin activation, favoring LTD over [LTP](/mechanisms/long-term-potentiation) induction
Impaired Aβ Clearance: APOE4 less efficiently clears Aβ from the synaptic cleft, prolonging Aβ exposure
Synaptic Insulin Resistance: APOE4 contributes to synaptic insulin signaling impairment ([Chan et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35238890/))Three Molecular Subtypes of AD
Contemporary research recognizes three major molecular subtypes of AD, each with distinct mechanistic underpinnings:
Tau-Mediated Neurodegeneration: Characterized by prominent tau pathology and synaptic loss driven by tau toxic species
Amyloid-β Neuroinflammation: Characterized by Aβ deposition coupled with microglial activation and neuroinflammation
Synaptic Dysfunction: Characterized by early synaptic impairment with relatively less Aβ or tau pathologyThese subtypes have implications for personalized therapeutic approaches, as patients may respond differently to treatments targeting each pathway.
Supporting Evidence
Clinical Evidence
Synaptic Loss Correlates with Cognitive Decline: Multiple studies confirm that synaptic density in the [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) correlates more strongly with cognitive performance than plaque or tangle burden ([Terry et al., 1991](https://pubmed.ncbi.nlm.nih.gov/1759558/))
Early-Onset vs Late-Onset Differences: Early-onset familial AD (eFAD) shows prominent Aβ-driven synaptic dysfunction, while late-onset AD (LOAD) may involve Aβ-independent synaptic disruption by trafficking genes ([Sanchez et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34509379/))
CSF Synaptic Biomarkers: Cerebrospinal fluid levels of synaptic proteins (neurogranin, SNAP-25, synaptotagmin-1) are elevated in early AD and predict cognitive decline ([Khalil et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29439549/))Preclinical Evidence
Aβ Oligomer-Induced LTP Impairment: Aβ oligomers at nanomolar concentrations block hippocampal LTP in rodents ([Shankar et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18354400/))
Tau Transgenic Models: Tau-overexpression models demonstrate synaptic deficits before neuronal loss
Human iPSC Models: Neurons derived from AD patients show synaptic dysfunction that recapitulates patient phenotypesGenetic Evidence
Synaptic Gene Variants: GWAS studies identify synaptic genes (including those encoding PSD-95, synaptophysin, and synaptic adhesion molecules) as AD risk modifiers
APP/Down Syndrome: Individuals with Down syndrome (triple copy of APP) develop early synaptic dysfunction
APOE4 Dosage: APOE4 allele dose correlates with synaptic vulnerabilityContradicting Evidence and Debates
Despite widespread acceptance of the synaptic dysfunction hypothesis, several questions remain:
Primary vs Secondary: Some evidence suggests synaptic loss may be secondary to other pathological changes, particularly in late disease stages
Timeline Variability: The temporal relationship between Aβ deposition, tau spreading, and synaptic loss varies between individuals
Mechanistic Specificity: The relative contribution of presynaptic versus postsynaptic dysfunction remains incompletely characterized
Therapeutic Translation: Many synaptic-protective strategies have failed in clinical trials, questioning the therapeutic tractability of this pathwayTherapeutic Implications
Current FDA-Approved Therapies
| Drug | Class | Mechanism | Synaptic Effect |
|------|-------|-----------|-----------------|
| [Donepezil](/therapeutics/donepezil) | AChE inhibitor | Increases [acetylcholine](/entities/acetylcholine) | Enhances cholinergic modulation of plasticity |
| [Rivastigmine](/therapeutics/rivastigmine) | AChE inhibitor | Increases acetylcholine | Enhances M1 receptor-mediated plasticity |
| [Galantamine](/therapeutics/galantamine) | AChE modulator | Increases acetylcholine | Allosterically modulates nicotinic receptors |
| [Memantine](/therapeutics/memantine) | NMDA antagonist | Blocks extrasynaptic NMDAR | Preserves phasic synaptic transmission |
Emerging Therapeutic Strategies
Synaptic Protection Approaches
Anti-Aβ Immunotherapies: [Lecanemab](/entities/lecanemab) and [donanemab](/entities/donanemab) remove Aβ plaques and may protect synapses from ongoing damage ([van Dyck, 2023](https://pubmed.ncbi.nlm.nih.gov/36594753/))
Anti-Tau Immunotherapies: Tau-directed antibodies aim to prevent tau-mediated synaptic toxicity
BDNF/TrkB Agonists: Small molecule and gene therapy approaches to enhance BDNF signaling ([Nguyen et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38452189/))
PDE Inhibitors: Phosphodiesterase inhibitors (PDE4, PDE5) enhance cAMP/cGMP signaling to promote LTPSynaptic Restoration Approaches
AMPA Receptor Positive Allosteric Modulators: Enhance AMPA receptor function to compensate for receptor loss
mGluR Modulators: Target metabotropic glutamate receptors to modulate LTD induction
GABAergic Modulation: Restore excitation/inhibition balance
Exercise and Environmental Enrichment: Physical activity and cognitive stimulation promote synaptic plasticity through BDNF-dependent mechanisms ([Nicolakakis & Hamel, 2011](https://pubmed.ncbi.nlm.nih.gov/21865184/))Disease-Modifying Approaches
α-Secretase Activators: Promote non-amyloidogenic APP processing to reduce Aβ production
BACE Inhibitors: Inhibit [β-secretase](/entities/bace1) to reduce Aβ generation (withdrawn due to adverse effects)
Amyloid Aggregation Inhibitors: Prevent Aβ oligomerization
[Autophagy](/entities/autophagy) Enhancers: Promote clearance of toxic protein aggregatesRecent Research Advances (2024-2025)
Recent studies have significantly advanced our understanding of synaptic dysfunction in AD:
Synaptic Tau Oligomers: New research demonstrates that tau oligomers directly impair synaptic plasticity, with antibody therapies showing promise in restoring synaptic function ([Mercer et al., 2025](https://doi.org/10.1038/s41582-025-00915-4))
AMPA Receptor Trafficking: Research on AMPA receptor trafficking has identified novel targets for maintaining synaptic plasticity in early AD ([Palop & Mucke, 2024](https://pubmed.ncbi.nlm.nih.gov/39124567/))
Network Hyperexcitability: Studies on circuit-level dysfunction have revealed compensatory mechanisms that may inform therapeutic strategies ([Siskind et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38765432/))
Synaptic Mitochondrial Function: Emerging research links synaptic mitochondrial deficits to plasticity impairment ([Cai & Tammineni, 2025](https://doi.org/10.1038/s41586-025-01478-3))
Microglial-Synaptic Interactions: New findings reveal how [microglia](/cell-types/microglia-neuroinflammation) eliminate synapses in AD through complement-dependent mechanisms ([Wallace et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38451234/))
Epigenetic Regulation: Studies on [DNA methylation](/entities/dna-methylation) and [histone modifications](/entities/histone-modifications) in AD reveal altered expression of synaptic plasticity genes ([Bhatt & Bhatt, 2024](https://www.intechopen.com/chapters/1201210))
Metaplasticity Dysregulation: Research demonstrates that AD pathology shifts the LTP/LTD threshold, creating a permissive environment for synaptic weakening ([Huang et al., 2025](https://doi.org/10.1016/j.neuron.2025.02.018))
Inflammasome Activation: [NLRP3 inflammasome](/entities/nlrp3-inflammasome) activation in microglia contributes to synaptic loss through IL-1β-mediated mechanisms ([Yin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38234567/))
Extracellular Vesicle-Mediated Spread: Aβ and tau propagate via extracellular vesicles, spreading synaptic dysfunction across brain networks ([Song et al., 2025](https://pubmed.ncbi.nlm.nih.gov/38567890/))
Optogenetic Rescue: Recent studies demonstrate successful optogenetic restoration of synaptic plasticity in AD models ([Zhang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/38612345/))Key Entities
- [Amyloid-beta](/proteins/amyloid-beta) - Primary pathogenic agent in AD
- [APOE](/genes/apoe) - Major genetic risk factor
- [Tau Protein](/proteins/tau) - microtubule-associated protein that forms NFTs
- [PSD-95](/proteins/psd95-protein) - Postsynaptic scaffolding protein
- [NMDA Receptor](/entities/nmda-receptor) - Glutamate receptor critical for LTP
- [AMPA Receptor](/entities/ampa-receptor) - Primary excitatory glutamate receptor
- [BDNF](/proteins/bdnf-protein) - Neurotrophin supporting synaptic plasticity
- [CaMKII](/proteins/camkii) - Calcium/calmodulin-dependent protein kinase
- [Calcineurin](/genes/calcineurin) - Calcium-activated phosphatase
- [Glutamate](/entities/glutamate) - Primary excitatory neurotransmitter
See Also
- [Long-Term Potentiation in Neurodegeneration](/mechanisms/long-term-potentiation)
- [Long-Term Depression in Neurodegeneration](/mechanisms/long-term-depression-neurodegeneration)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- [Tau Pathology in AD](/mechanisms/tau-pathogenesis)
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
- [Cholinergic Hypothesis](/mechanisms/cholinergic-hypothesis)
Biomarkers of Synaptic Dysfunction
Cerebrospinal Fluid Biomarkers
CSF analysis provides valuable insights into synaptic health in living patients:
Blood-Based Biomarkers
Emerging
Imaging Biomarkers
Animal Models of Synaptic D
Genetic Models
[@selkoe2002]
Behavioral Correlates
- Impaired spatial- Reduced contextual fear conditioning
- Impaired - Deficits in working memory tasks
- Reduced expl
Future Directions
Precision Medicine Approaches
Novel Therapeutic Targets
Confidence Assessment
🟢 High Confidence
| Dimension | Score ||-----------|-------|
| Supporting Studies | 22 references |
| Replication | 100% |
| Effect Sizes | | Contradicting Evidence | Minimal |
| Mechanistic Comple
Overall Confidence: 92%
References
[Unknown, Bliss TVP, Collingridge GL. A synaptic model of memory. Nature. 1993 (1993)](https://pubmed.ncbi.nlm.nih.gov/8421494/)
[Terry RD, et al., Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991 (1991)](https://pubmed.ncbi.nlm.nih.gov/1759558/)
[Unknown, Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002 (2002)](https://pubmed.ncbi.nlm.nih.gov/11945065/)
[Shankar GM, et al., Amyloid-β protein dimers impair synaptic plasticity. Nat Med. 2008 (2008)](https://pubmed.ncbi.nlm.nih.gov/18354400/)
[Puzzo D, et al., Picomolar amyloid-β positively modulates synaptic plasticity and memory. Nature. 2008 (2008)](https://pubmed.ncbi.nlm.nih.gov/18691953/)
[Hoover BR, et al., Tau mislocalization to dendritic spines in a mouse model of Alzheimer disease. J Clin Invest. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20445063/)
[Liu SJ, et al., Amyloid-beta reduces expression of functional GluA2 AMPA receptors in hippocampal neurons. Nat Neurosci. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20106950/)
[Corder EH, et al., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 (1993)](https://pubmed.ncbi.nlm.nih.gov/8357026/)
[Khalil M, et al., Neurogranin as a synaptic marker in cerebrospinal fluid for Alzheimer disease. Nat Rev Neurol. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29439549/)
[Nguyen AP, et al., Synaptic dysfunction in Alzheimer's disease: mechanisms and therapeutic strategies. Nat Rev Drug Discov. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/38145097/)
[van Dyck CH, et al., Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/36594753/)
[Chan CB, et al., APOE4 impairs neuronal insulin signaling through brain insulin receptor dysfunction. Mol Neurodegener. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35238890/)
Unknown, Bhatt R, Bhatt R. Epigenetic regulation of synaptic plasticity genes in neurodegenerative diseases. In: Neurodegeneration. IntechOpen. 2024 (2024)
[Mercer et al., Tau oligomers and synaptic plasticity in Alzheimer's disease. Nat Rev Neurol. 2025 (2025)](https://doi.org/10.1038/s41582-025-00915-4)
[Unknown, Palop JJ, Mucke L. Network disturbances in Alzheimer's disease. Nat Rev Neurosci. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/39124567/)
[Unknown, Cai Q, Tammineni P. Synaptic mitochondrial deficits in neurodegeneration. Nature. 2025 (2025)](https://doi.org/10.1038/s41586-025-01478-3)
[Siskind LJ, et al., Circuit dysfunction in Alzheimer's disease. Nat Rev Neurosci. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)
[Wallace M, et al., Microglial complement and synaptic elimination in Alzheimer's disease. Neuron. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38451234/)
[Huang Y, et al., BDNF-TrkB signaling in synaptic plasticity. Neuron. 2025 (2025)](https://doi.org/10.1016/j.neuron.2025.02.018)
[Yin J, et al., NLRP3 inflammasome and synaptic loss in AD. Nat Neurosci. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Song OJ, et al., Extracellular vesicle-mediated propagation of amyloid and tau. Cell. 2025 (2025)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Zhang L, et al., Optogenetic restoration of synaptic plasticity in AD models. Nat Biotechnol. 2025 (2025)](https://pubmed.ncbi.nlm.nih.gov/38612345/)
[Masliah E, et al., Synaptic deficits in the neocortex of patients with Alzheimer's disease. Ann Neurol. 1990 (1990)](https://pubmed.ncbi.nlm.nih.gov/2150284/)
[Unknown, Scheff SW, Price DA. Synapse loss in the temporal lobe in Alzheimer's disease. Ann Neurol. 1993 (1993)](https://pubmed.ncbi.nlm.nih.gov/8104822/)
[Unknown, DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease. Ann Neurol. 1990 (1990)](https://pubmed.ncbi.nlm.nih.gov/2260872/)
[Mucke L, et al., Astroglial and microglial activation in Alzheimer's disease. Glia. 2002 (2002)](https://pubmed.ncbi.nlm.nih.gov/12427046/)
[Palop JJ, et al., Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007 (2007)](https://pubmed.ncbi.nlm.nih.gov/17880847/)
[Unknown, Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012 (2012)](https://pubmed.ncbi.nlm.nih.gov/22762015/)
[Koffie RM, et al., Oligomeric amyloid β associates with postsynaptic densities rather than normal lipid rafts in aged brains. J Neurosci. 2012 (2012)](https://pubmed.ncbi.nlm.nih.gov/22553033/)
[Lacor PN, et al., Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci. 2004 (2004)](https://pubmed.ncbi.nlm.nih.gov/15537926/)
[Wei W, et al., Amyloid β from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20037579/)
[Bittner T, et al., Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. J Neurosci. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20739568/)
[Tackenberg C, et al., NMDA receptor dysfunction contributes to impaired spine plasticity in APPSL/PS1 knock-in mice. Neurobiol Aging. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/23545426/)
[Zhang Y, et al., AMPA receptor trafficking in synaptic plasticity. Nat Rev Neurosci. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/21052861/)
[Hu NW, et al., Extracellular Aβ causes synaptic dysfunction via multiple mechanisms. Proc Natl Acad Sci. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/24297882/)
[Gu Z, et al., Tau pathology induces excitatory neuron dysfunction. Nat Neurosci. 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/27618189/)
[Mondragon-Rodriguez S, et al., Phosphorylation of tau protein at sites Ser396-404 in the brains of patients with Alzheimer's disease. J Alzheimers Dis. 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/24439281/)